Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05086692
Other study ID # MDNA11-01
Secondary ID KEYNOTE-E53MK347
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 27, 2021
Est. completion date December 30, 2026

Study information

Verified date March 2024
Source Medicenna Therapeutics, Inc.
Contact Nina Merchant
Phone 604-340-3081
Email nmerchant@medicenna.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.


Description:

The study drug, MDNA11, long-acting "beta-only" recombinant interleukin-2 (rIL-2). MDNA11 specifically engineered to overcome the shortcomings of rhIL-2 (aldesleukin) by preferentially activating immune effector cells (CD8+ T- and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. It is designed to potentially enhance host immune response and fusion to albumin increases the half-life further avoiding frequent dosing required with rhIL-2. The study will be conducted at up to 30 clinical sites following regulatory authority and institutional review board / independent ethics committee (IRB/ IEC) approval and completion of informed consent. The study will be conducted in multiple parts: - Monotherapy (MDNA11 alone) dose escalation - Monotherapy (MDNA11 alone) dose expansion in select tumor types - Combination (MDNA11 + pembrolizumab) dose escalation - Combination (MDNA11 + pembrolizumab) dose expansion in select tumor types Approximately 115 patients will be enrolled. After commencing treatment (first exposure of MDNA11 alone or MDNA11 + pembrolizumab), tumor assessment by CT/MRI will be performed every 8 weeks ± 1 week until immune confirmed progressive disease ("iCPD") by iRECIST, discontinuation of study drug(s), withdrawal of consent or loss to follow-up. Treatment beyond progression may be permitted if criteria are met. Patients can withdraw from participation at any time.


Recruitment information / eligibility

Status Recruiting
Enrollment 115
Est. completion date December 30, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures. 4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions) 5. Demonstrated adequate organ function 6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and/or MRI. 7. Life expectancy of = 12 weeks. 8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding. 9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control. Key Exclusion Criteria: 1. Last administration of prior antitumor therapy: - Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment. - Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (<2 weeks of radiotherapy) to non-CNS disease. - Radiation therapy to the lung that is > 30Gy within 6 months prior to start of treatment. - Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval. 2. Has known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM. 3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers. 4. Condition requiring long-term systemic treatment with either corticosteroids > 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment. 5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy. 6. Severe pulmonary, cardiac or other systemic disease. 7. Known hepatitis B or C virus infection. 8. Females who are pregnant or lactating or planning to become pregnant during the study. 9. Has had an allogeneic tissue/solid organ transplant. 10. Active infection requiring systemic therapy. 11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol 12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events. 13. Known severe hypersensitivity to any component of study drug(s). 14. Inability to comply with study and follow up procedures as judged by the Investigator.

Study Design


Related Conditions & MeSH terms

  • Acral Melanoma
  • Advanced Solid Tumor
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Carcinoma
  • Carcinoma, Basal Cell
  • Carcinoma, Merkel Cell
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Ovarian Epithelial
  • Carcinoma, Renal Cell
  • Carcinoma, Squamous Cell
  • Cervical Cancer
  • Clear Cell Renal Cell Carcinoma
  • Cutaneous Melanoma
  • Cutaneous Squamous Cell Carcinoma
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Epithelial Ovarian Carcinoma
  • Esophageal Cancer
  • Fallopian Tube Cancer
  • Fallopian Tube Neoplasms
  • Gastric Cancer
  • Lung Neoplasms
  • Melanoma
  • Merkel Cell Carcinoma
  • Mesothelioma
  • MSI-H Solid Malignant Tumor
  • Mucosal Melanoma
  • Neoplasms
  • Ovarian Cancer
  • Pleural Mesothelioma
  • Primary Peritoneal Cancer
  • Skin Cancer
  • Solid Tumor
  • Solid Tumor, Adult
  • Squamous Cell Carcinoma of Head and Neck
  • Triple Negative Breast Cancer
  • Triple Negative Breast Neoplasms

Intervention

Drug:
MDNA11
MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
Pembrolizumab
MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).

Locations

Country Name City State
Australia Gallipoli Medical Research Foundation Greenslopes Queensland
Australia Scientia Clinical Research Randwick New South Wales
Australia Macquarie University Sydney New South Wales
Canada Princess Margaret Cancer Center Toronto Ontario
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do
Korea, Republic of Samsung Medical Center Seoul Gangnam-gu
Korea, Republic of Seoul National University Hospital Seoul Jongno-gu
Korea, Republic of The Catholic University of Korea St. Vincent Hospital Suwon-si Gyeonggi-do
United States Emory - Winship Cancer Institute Atlanta Georgia
United States Johns Hopkins Hospital Baltimore Maryland
United States Boca Raton Regional Hospital Boca Raton Florida
United States Karmanos Cancer Institute Detroit Michigan
United States MD Anderson Cancer Center Houston Texas
United States Orlando Health Cancer Institute Orlando Florida
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Providence Saint John's Health Center Santa Monica California

Sponsors (2)

Lead Sponsor Collaborator
Medicenna Therapeutics, Inc. Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Analysis of immune characteristics of the tumor microenvironment Measured by change in Tumor Infiltrating Lymphocyte (TIL) levels Up to 24 months
Primary MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) Evaluation of tolerability as measured by number of patients with dose limiting toxicities (DLTs) 24 months
Primary Incidence of Treatment Related Adverse Events (TRAEs) Rate of TRAEs in patients with advanced solid tumors 24 months
Primary Incidence of Treatment Emergent Adverse Events (TEAEs) Rate of TEAEs in patients with advanced solid tumors 24 months
Secondary Pharmacokinetic characteristics on MDNA11 - Cmax (ug/mL) Maximum observed serum drug concentration Up to 24 months
Secondary Pharmacokinetic characteristics on MDNA11 - Tmax (h) Time to maximum observed serum drug concentration Up to 24 months
Secondary Pharmacokinetic characteristics on MDNA11 - AUClast (h.ug/mL) Area under the serum concentration vs time curve from time zero to the last measurable concentration Up to 24 months
Secondary Immunogenicity of MDNA11 (anti-drug antibodies) Incidence and persistence of anti-drug antibodies to MDNA11 Up to 24 months
Secondary Pharmacodynamic effects of MDNA11 Measurement of translational parameters - Flow cytometry analysis of immune cells in blood and serum measurements of cytokine levels Up to 24 months
Secondary Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Overall Response Rate (ORR) Assessed by RECIST v1.1 and iRECIST; CR+PR/Evaluable N Approximately 24 months
Secondary Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Disease Control Rate (DCR) CR+PR+SD/Evaluable N Approximately 24 months
Secondary Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Progression Free Survival (PFS) Time from signing ICF to disease progression Approximately 24 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2